Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

A cornerstone of preclinical cancer research has been the use of clonal cell lines. However, this resource has underperformed in its ability to effectively identify novel therapeutics and evaluate the heterogeneity in a patient's tumor. The patient-derived xenograft (PDX) model retains the hete...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobbin, Zachary C., Katre, Ashwini A., Steg, Adam D., Erickson, Britt K., Shah, Monjri M., Alvarez, Ronald D., Conner, Michael G., Schneider, David, Chen, Dongquan, Landen, Charles N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226719/
https://www.ncbi.nlm.nih.gov/pubmed/25209969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226719/
https://www.ncbi.nlm.nih.gov/pubmed/25209969

Ejemplares similares